Illumina, Inc. (ILMN) Earnings Call Transcript & Summary
November 4, 2024
Earnings Call Speaker Segments
Salli Schwartz
executiveHello, everyone, and thank you for being here on the call about our third quarter of 2024. Today we'll review the financial results we released after the market closed, then share some thoughts on our commercial activity, and after that we'll take questions and answers. Our earnings release is available in the Investor Relations section of our website, Illumina.com. Speaking for Illumina today will be our Chief Executive Officer, Jacob Tyson, and our Chief Financial Officer, Ankur Dhingra. Jacob will provide an update on how Illumina's business is doing, and Ankur will take us through the financial results for Core Illumina. Before we begin, a quick note that GRAIL was sold off this past June. For anyone wanting to look back at how GRAIL and Consolidated Illumina performed financially in earlier periods, those details are available in our earnings release and SEC filing. Our discussion today will center on non-GAAP figures, and those do factor in stock-based compensation. We'd encourage you to look over the GAAP reconciliation for these non-GAAP metrics, which is included in today's release as well as the supplementary data on our website. Before we get into the numbers, a couple of quick notes. When we say year over year, we're comparing to the third quarter of fiscal 2023, and when we say sequential, that's a comparison to the second quarter of fiscal 2024. Also, this call is being recorded, and you'll be able to find the audio in the Investor section of our website. Everything we say today about our financial results and commercial activity that looks ahead is intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements carry risks and uncertainties, and what actually happens could differ materially from what we project or discuss. These statements reflect only what we know right now, and Illumina has no obligation to update them. For a clearer picture of the risks and uncertainties that might make actual outcomes come out differently, please look at the filings Illumina submits to the Securities and Exchange Commission — among them Illumina's latest forms 10-Q and 10-K. With that said, I'll hand the call over to Jacob now.
Jacob Thaysen
executiveThanks, Salli. Good afternoon, everyone, and I appreciate you all being on the call today. Illumina turned in yet another quarter of robust financial results. We're achieving meaningful headway when it comes to widening margins and boosting earnings, increasing how much the NovaSeq X platform is being used, and delivering the next stage of sequencing breakthroughs to our customers. During Q3, we recorded $1.1 billion in revenue, which matched what we had anticipated. Looking at our geographies, America's revenue declined 6% year-over-year, Europe revenue climbed 12%, EMEA revenue rose 7%, and Greater China fell 23%. During the quarter, we added 58 more NovaSeq X Plus instruments, which lifted our total installed base to 527. Roughly 40% of that installed base has gone to clinical customers, which speaks to how varied our user base is. The X-Series crossed $1 billion in cumulative revenue, which is a significant milestone. Our non-GAAP operating margin came in at 22.6%, and diluted earnings per share reached $1.14, both above what we had expected, and we started putting into action the capital allocation strategy we presented at our August Strategy Update. As we look toward the rest of the year, although the funds remain healthy, the near-term macroeconomic backdrop has stayed persistently tight. We now anticipate that our 2024 revenue growth will come in slightly below our earlier guidance range. That said, we are increasing our guidance for both 2024 operating margin and earnings per share, which mirrors the considerable headway we've achieved so far this year on our transformative journey, pursuing operational excellence and reinforcing our culture of performance. Ankur will share more specifics when he speaks. At our August Strategy Update, we presented a plan to generate high single-digit revenue growth along with 500 basis points of operating margin expansion by 2027, while delivering annual EPS growth in the double-digits to teens across the next three years. To get there, I've established key priorities to steer execution against our strategy: deeper customer collaboration, continuous innovation, and a commitment to operational excellence and margin expansion. Our first priority, deeper customer collaboration, focuses on delivering a range of targeted solutions that serve the increasingly diverse needs of our customer base. Over the past several months, I've kept connecting with our customers around the world. Most recently, that included a group of academic core lab directors who have a long legacy of collaboration with Illumina and rank among our most experienced users. I'm grateful to them for their continued partnership and support. As we evolve how we engage with customers, we've concentrated on two key initiatives. One, changing how we interact and collaborate with customers to support their ambitions. My observation was that we needed to improve in this area. And now I'm starting to hear from customers that they're seeing Illumina show up in a new way. And two, giving customers a clear line of sight to the significant innovations we have in the pipeline. Their early input is invaluable, allowing us to develop the most impactful products and solutions in the industry. It makes me happy to witness this collaborative attitude taking deeper root within the culture of our organization; moving forward, it will act as a key foundation for the success we achieve. Continuous innovation stands as our number two objective, and it flows logically out of our number one objective since it is propelled and molded by what our customers communicate to us about their requirements. To illustrate, we unveiled not long ago the introduction of the revolutionary MiSeq i100. We are responding to the need for adaptable options suited to smaller-scale initiatives that require quicker completion times. Initial reactions are confirming that our strategy of involving customers as advisers during the entire product creation journey is the right one. Customers are enthusiastic about shipping and storage conditions at room temperature, which make it possible to perform sequencing whenever needed without having to keep reagents on hand. The reduced runtimes, combined with 18 established end-to-end workflows, represent exactly what those we serve have requested; and they have described this as a transformative development. As time goes on, we plan to apply these emerging technologies in upcoming releases spanning our entire portfolio. Shipments of MiSeq i100 instruments to early access customers are set to start in late Q4, fueled by the robust demand observed in the days right after the announcements. During our strategy update, we presented several other innovations, such as comprehensive whole genome sequencing and our five-phase genome, which is scheduled to roll out across the coming 12 to 18 months. Taken together, these technologies will transform genome while simplifying the NGS workflow. The comprehensive whole genome offering utilizes a unique constellation map read technology to introduce extra tiers of genomic information, expanding what the SPS chemistry is capable of producing. Standard library preparation is removed because it takes place straight on the flow cell, cutting the process from many hours of manual work down to merely a few minutes. The five-phase genome represents yet another innovation steered by customer needs, delivering variant and epigenetic data from one single library prep. Every run will give customers access to methylation data, which matters for comprehending conditions like cancer, obesity, and infectious diseases. The five-phase genome along with the constellation map read technology solutions are both in development right now, and feedback from customers will shape how our products evolve. Additional information about these two innovations, such as results from early access customers, will be shared by us at forthcoming industry gatherings, for instance ASHG later this week. In the short term, Illumina keeps rolling out innovations for the NovaSeq X Series. We are still on schedule to start shipping the single-flow cell NovaSeq X before this year concludes. This instrument can be upgraded to the NovaSeq X+; during Q4, we will bring out 100-cycle and 200-cycle 25B flow cells made for high-output counting uses, such as single-cell and proteomics. Operational excellence is our third objective. What we concentrate on here is creating a base that fuels our success over the long haul, no matter what happens with the top line. Through boosting efficiency, fine-tuning how we spend on investments, and ensuring smart allocation of capital, we are putting Illumina in a position to benefit directly not just our customers and the patients they care for, but our staff and our shareholders as well. Sure, we've come a long way in creating a culture where each employee is pushing efficiency gains that feed into operational excellence. At this point, I'll hand it to Ankur to walk through additional specifics regarding our third quarter results and outlook.
Ankur Dhingra
executiveThanks, Jacob, and good afternoon to all of you. I'll walk you through how we performed financially, offer additional detail on revenue, expenses, earnings, and what's happening with our balance sheet, then discuss what we expect looking ahead. Everything financial we're discussing, including the guidance provided on this call, relates solely to Core Illumina and leaves out GRAIL. In Q3, Illumina brought in $1.08 billion in revenue, which matched what we had anticipated, and through sustained cost control and operational excellence, the team achieved very robust margin and earnings growth. Our cash generation stayed solid, and we deployed cash across every aspect of our capital allocation strategy. Now let me provide more detail on each of those points. Q3 revenue declined 2% versus the prior year on a reported basis and also on a constant currency basis, as significant gains in consumables were offset by instruments falling off against launch year comparisons. Sequencing consumables brought in $741 million, a 7% increase versus the prior year, fueled by ongoing robust adoption of X consumables. The NovaSeq X transition moved ahead more quickly than we had projected. By the close of Q3, over 55% of high throughput gigabases sequenced and over 35% of high throughput consumables revenue came from the NovaSeq X series; we observed some speeding up of the shift from 6K to X during this quarter, including within clinical, as roughly 40% of high throughput clinical gigabases sequenced ran on the NovaSeq X series. As older assays move over to the X series, we've observed rising clinical volumes and growing uptake of the 25B flow cell among clinical customers. Although the pace of transition will fluctuate somewhat quarter to quarter depending on decisions our customers make, we continue to expect that nearly half of high throughput consumables revenue may shift to the X series by the middle of 2025. Turning to sequencing activity, total sequencing GB output across our connected high and mid throughput instruments kept expanding at a rate exceeding 40% versus the prior year, with solid growth from clinical and research customers alike. Sequencing instruments generated $104 million in revenue for Q3, a 42% drop versus the prior year, coming in slightly below what we expected. Two factors drove that year-over-year decrease. First, fewer NovaSeq X placements relative to the substantial pre-order launch related shipments during Q3 of 2023. And second, a reduction in mid throughput shipments as constraints on capital and cash flow keep weighing on purchasing behavior and tempering instrument placements around the world. Sequencing service and other revenue reached $150 million, rising 6% versus the prior year, propelled by higher revenue from strategic partnerships along with strong instrument service contract revenue on an expanding install base. Shifting to the remainder of the P&L, non-GAAP gross margin came in at 70.5% for the quarter, up 450 basis points versus the prior year. That impressive gross margin result stemmed mainly from carrying out our operational excellence initiatives, which keep enhancing productivity and generating cost savings. The gross margin gain compared with a year earlier also got a boost from a better revenue mix in sequencing consumables, which accounted for about half of that increase. Even though the mix of business will shift from one quarter to the next, the productivity gains we've delivered can be sustained and will help drive our margin expansion ahead. Non-GAAP operating expenses came to $517 million, essentially level with the previous quarter. That figure includes the extra headcount and costs tied to our purchase of Fluent BioSciences. The Illumina team keeps managing expenses well. As I noted during our strategy update, we have a number of actions underway to reprioritize and cut our expenses. Consequently, non-GAAP operating margin for the quarter reached 22.6%, up against the 22.5% recorded in the same period a year ago. That result landed well ahead of the roughly 20% we had guided, thanks to strong operational performance in gross margin as well as expense discipline. Beneath the operating income line, non-GAAP other expense totaled $14 million in Q3. In the quarter, we issued $500 million of debt carrying a 4.65% coupon, which was used together with cash on hand to fully redeem the costly $750 million delayed broad term loan, in effect de-levering and lowering our interest rate as well. The non-GAAP tax rate for the quarter stood at 21%; during Q3 we benefited from a few one-time credits when we filed last year's return. Adding everything up, non-GAAP net income for Q3 was $181 million, with diluted earnings per share of $1.14. Our non-GAAP weighted average diluted share count for the quarter came to about 160 million shares. Turning to cash flow and balance sheet items for the quarter, cash provided by operations was a healthy $316 million. Capital expenditures totaled $32 million, while free cash flow reached $284 million. During the quarter, we deployed cash consistent with our stated capital allocation strategy. We bought Fluent BioSciences, bringing innovative instrument-free single-cell technology into Illumina's portfolio. We're enthusiastic about what this technology could make possible for very large single-cell experiments. Beyond that, after our board gave authorization earlier in the quarter, we established a share repurchase program and bought back 770,000 Illumina shares for $98 million, at an average price of $127.71 each. And as I mentioned, we de-levered. All together, these capital moves demonstrate how strong our operational execution was in the quarter. We closed the quarter with roughly $939 million in cash, cash equivalents, and short-term investments. To sum up, revenue matched expectations. The shift of high-throughput sequencing toward the NovaSeq X is progressing quite well. We introduced breakthrough new products in low throughput. We advanced significantly toward our stated margin expansion goal, and we've been putting our strong cash flow to work toward revenue growth, better earnings, and shareholder-friendly capital actions. Now on to 2024 guidance. Even though our overall Q3 revenue results were in line with what we expected, we are tempering our revenue expectations for year-end business and now anticipate full-year revenue declining approximately 3%. Looking at Q4, our expectation is revenue of roughly $1.07 billion. Strong utilization levels and pull through on our instruments are things we keep seeing, but the near-term macroeconomic environment is still constrained and won't support any uptick in purchasing behavior through the end of the year. On the instruments versus consumables front, the projected mix hasn't changed, and our forecast still calls for instrument revenue to decline in the mid-30s percentage range relative to 2023. We're very excited about MiSeq 100, though it is in early access, and in Q4 we will receive minimal revenue contribution from it. As we had planned for, our low-throughput instrument business will likely decline in Q4, with customers waiting for the new instrument; for high throughput, second-half NovaSeq X shipments are still expected to be above what we delivered in the first half of 2024. Sequencing consumables revenue is also still forecast to grow towards the upper end of the low single-digit percentage range versus 2023. We saw strong uptake and GB usage in the third quarter, setting the stage for exiting the year with solid year-over-year consumables growth. While our lower revenue guidance is disappointing to us, we are increasing our guidance for operating margin and diluted EPS, reflecting both the outperformance in Q3 and carrying forward the impact of our operational excellence initiatives into Q4. Our non-GAAP operating margin guidance is being raised to a range of 21% to 21.5% for 2024; our projected tax rate for the year is being reduced to approximately 24%. And lastly, our guidance range for non-GAAP diluted earnings per share is being raised to $4.05 to $4.15 range for full year 2024. With that, I will now turn it back over to Jacob for his closing remarks. Thank you.
Jacob Thaysen
executiveAppreciate that, Ankur. Looking back over my initial 12 months, I feel a lot of enthusiasm about the quick strides Illumina has taken and the drive we've built up to move this industry ahead; we sharpened our focus on the solid foundation of our primary business and rolled out our fresh strategy. We overhauled the leadership group and implemented the structural adjustments required to back our customer-first approach. Operational excellence has been woven more and more into how we operate, and that's starting to come through in our financial numbers. It's a promising beginning to what will be a transformation spanning multiple years. When it comes to 2025, we anticipate getting back to growth, though I'd prefer to wrap up Q4 first before giving any detailed guidance. In the end, I'm heartened and have faith that Illumina can return to high single-digit revenue growth by 2027, just as we said in our strategy update. Thanks for being here today. At this point I'll ask the operator to open up the line for Q&A.
Doug Schenkel
analystRegarding your guidance, and bearing in mind you're steering revenue to decline marginally on a sequential basis, which areas do you anticipate falling off? And more precisely, are you expecting sequenced and consumable revenue to increase quarter over quarter, and sort of extending from that thought? Looking at it clinically, you're achieving quite strong strides when it comes to placements among clinical customers. Once a box is placed, what level of insight do you have into that customer's intentions? To put it another way, can you tell when current assays will shift off a legacy instrument onto the X? I'm simply seeking something to help calm worries about a clinical cliff regarding consumable revenue as we peer toward '25. Thank you.
Jacob Thaysen
executiveYeah, I appreciate that. This phrase "clinical cliff" has come up several times, and that isn't how we view the business at present, in my opinion. I believe, above all, we're obviously thrilled to observe that strong momentum toward the X keeps building. As Ankur noted earlier, that robust momentum is what we're witnessing. A great deal of volume is shifting in the direction of the X. So all signs are aligning with what we likewise laid out during the Strategy Day. Just as you pointed out too, we did lower it, and we were adjusting the guidance here as we moved out of Q3 and into Q4. Since we haven't observed — despite a very healthy instrument funnel — the typical end-of-year activity we'd ordinarily witness; yet, as you're noting as well, we truly did see a really pleasant uptick in our consumables revenue. That, I believe, is also what we stated previously: a powerful signal that we're witnessing the trajectory shifting toward the X. On the particulars around clinical and around how much transparency we have with our customers, we actually devote quite a lot of time, particularly with our bigger customers. Like I said earlier, we're investing a lot of time genuinely collaborating closely with them to grasp where they'll truly go further into where we stand with our funnel and what sits in our R&D pipeline, so they can be ready to make the transition when new technologies arrive from us. That applies to our academic customers as well as, most definitely, our clinical customers. We likewise possess a fairly solid grasp of the various projects they're exploring and the timing of their move onto the X. Now, from a high-level vantage point, I'd say we don't observe many customers shifting entirely from 6K across to X within just a few months; typically this happens assay by assay, and it requires time. Transitioning onto the X generally takes a year, or even 18 months; yet, as Ankur also pointed out, we've now witnessed over 40% of the volume for the clinical accounts.
Ankur Dhingra
executiveAnkur here. Doug, regarding that other point you raised, specifically your question about what we're guiding for in Q4 consumables: what our guidance currently bakes in is the usual seasonal step-down in consumables as we move from Q3 into Q4. Q4, as you're aware, contains a lot of holidays compared with the other quarters. I also went back and reviewed the patterns from the past few years; and on a seasonal basis, purchases of consumables do tend to track that downward seasonal pattern in Q4, and that is what I have built into the guide at this point. There's nothing underlying there from the standpoint of a transition, or a clinical transition, etc. — just simple seasonality.
Puneet Souda
analystI simply wanted to get some clarity regarding mid-throughput — did that drop mostly originate in China, or did the decrease this quarter in the U.S. and Europe reflect greater competition from a rival in mid-throughput based in the U.S.? Then, a quick question on 2025: I realize giving a figure is difficult for you there, but could you take us through what you're considering for 2025? Clearly one of the largest factors is the clinical transition for customers as they make the switch — naturally they'll buy new instruments, which brings revenue, yet simultaneously they'll be adopting a lower cost, which cuts the revenue you receive. So could you just take us through the considerations as you look at 2025? Thank you very much.
Jacob Thaysen
executiveAll right. Appreciate that; and Puneet, I think, let me begin with the first one, which is that I think we keep seeing a great deal of competition around the globe. I'm genuinely fairly encouraged about China. So about half a year ago, a new leader came into our China operation — that's Jenny — and she's really excelled at getting the organization reorganized and reconfigured, while also rebuilding ties with many of our partners and taking a look at a fresh approach to pricing. What I'd say is that this is starting to bear fruit for us, since on a sequential basis revenue there is beginning to level off, so at the very least the pattern in China is starting to change. Declaring any kind of turnaround would be premature, though. On the subject of competition in other parts of the world — you're spot on that the mid-throughput segment is where we're facing the heaviest competitive pressure. I want to be clear that this is something we treat with real seriousness — I've mentioned that before — but honestly, I think having rivals out there keeps us sharp, and I genuinely think it's important for any business. It pushes us to move faster and to show up stronger for the people we serve, so personally, I welcome it. If you examine how mid-throughput has been doing on its own, I recently had a discussion — which I brought up earlier — with the academic Core Lab directors. While we were talking, we also looked at where their business originates, and what we're noticing more and more is that they're seeing plenty of customers — small biotech firms, all those smaller players that in the past would have purchased a mid-throughput instrument, something likely, and handled sequencing in-house. Given the money tightness they're facing at the moment, a lot of them are turning to outsourcing, and we continue to observe — and because of that, those lab directors are going to see a greater share of that business. As we've said, the broader economy continues to account for most of the strain we're seeing in mid-throughput. Regarding 2025, I'd rather hold off on speculating about what it may bring until we've closed out this current year. That said — as I noted during the strategy day — our expectation, which we stay firmly committed to, is high single-digit growth by 2027. We also said back then that we're steadily working toward it, and we expect to shift from negative growth in 2024 into positive territory in 2025.
Vijay Kumar
analystJacob or Ankur, perhaps you both could weigh in with a lot of specifics here. Activity levels came in around 40%, yet I didn't catch any pricing discussion for GB. Did that align with the minus 20, minus 25 you had forecast at the Analyst Day? And with these mixed margin effects — sorry — I believe at the close of the Analyst Day you mentioned 500 basis points of margin expansion. Does that build off the revised margin base of 21 to 21.5, or ought we recalibrate that expansion in light of the raised guide for fiscal '24?
Jacob Thaysen
executiveWell, to start, I appreciate that, Vijay, and I'll have Ankur address the specifics within the guidance here, though I will say I'm quite encouraged to watch us deliver on our GM growth margin, along with our operating margin and EPS. I believe that says a great deal about the Illumina team and the company we aim to be, that even in tough times, we can still achieve meaningful progress in expanding margins. So that excites me, and I think it offers some very strong proof points that we remain highly committed to delivering the 500-basis point target we laid out at the Strategy Day. But, Ankur, would you like to remind everyone where we stand?
Ankur Dhingra
executiveCertainly, Vijay — regarding that pricing matter, I believe I addressed your initial question earlier. That's right, it fell within the 25-percentage range. You mentioned that because the shift from 6K to X sped up, during this quarter the price effect landed at the upper portion of that band — nearer to 25 than to 20 — yet it remained inside the range our model allows. Turning to margins, I can say the outcomes make me quite happy. When I consider the 500 basis points, using 21% as the starting point from which that 500 basis point growth is measured, it rests on a pair of factors, correct? First, our capacity to grow gross margins and stay within the high 60s to 70% band. What the team has managed to accomplish is to push that model harder and begin showing us what it might become as we continue raising it. We retain plenty of room to remove cost from COGS so we can structurally move nearer to that 70%; as things stand, in this quarter a richer mix definitely helped. Then, regarding OPEC, once more there are multiple levers available, but considering that 21% figure, where we finish this quarter, and how 2024 looks as it closes, I feel quite confident about the headway we are achieving.
Dan Brennan
analystFirst off, apologies — I jumped on the call a bit late. I know you touched on data growth somewhat, if I recall, but could you unpack how we should view NGS consumable revenue expansion when splitting the research customer base against the clinical customer base for Q3, and also how that tracked relative to what was expected?
Ankur Dhingra
executiveSure. I believe I can do that. I'm not certain you're laying it out in a very clear way, yet on the whole our consumables growth came in at up 6% for the quarter, and beyond that, research and clinical each grew well. There wasn't a dramatic shift between the two.
Dan Brennan
analystAll right. Perhaps backing up a bit regarding the sort of forecast for the sort of instruments you talked about, might you share some detail on what is presently assumed in the entire year guidance on a mid-throughput foundation? I believe you folks didn't offer any sort of split during the quarter regarding what the mid-throughput placements amounted to, yet I'm aware they came in soft. So whatever arithmetic or whatever detail you might give us concerning that mid-throughput figure and the sort of thing now baked in for the whole year?
Jacob Thaysen
executiveYeah. So right now, we aren't supplying the real placement figure for mid-throughput. We'll provide an update covering the entire year at the JPMorgan like we typically do. And I think, Ankur, perhaps you're a bit, you'd like to return to margins?
Ankur Dhingra
executiveRight, the order. Correct. That's on me. Consumables increased by 7% this quarter rather than 6%. And indeed, both research and clinical are seeing solid growth.
Dan Brennan
analystPerhaps I could squeeze in a different question regarding the X? I mean, is it reasonable to assume, even though you aren't providing any commentary on 25 right now, and I realize we're dealing with a tough CapEx situation, but is it reasonable to think about X placements in 25? Would it probably begin lower compared to 24 on a year-over-year basis, or is that just too soon to determine given the sort of environment we find ourselves in?
Jacob Thaysen
executiveYes. As I said, we would prefer to provide that guidance once we are ready to do so, by the start of the year.
Tycho Peterson
analystLet's spend a moment on how the move to clinical X appears to be unfolding. It looks like things may be gaining some traction. As we look ahead, what's your view on the pricing pressure that comes with it? Clearly the cost per gig is lower, and then there's the situation where certain oncology customers are tied into multi-year contracts, around GRAIL, that they managed to sign. I guess the question is whether those fall apart with the shift to X. How should we understand those dynamics?
Jacob Thaysen
executiveBroadly speaking, it goes without saying that we're happy to keep watching our customers shift in the direction of X. Our view is that the X platform delivers meaningful value to our customers, partly through a lower price point, and partly through the workflows it makes possible, together with the Dragon compute power at our disposal and the interpretation capability we have; so plenty of factors explain why our customers are eager to adopt the X. Yet, as you're aware too, within the clinical segment, a great deal of prep work is required, validation and similar steps, to ensure you're set to migrate all your assets. There's another angle as well: if you find yourself developing a new kind of asset, you may prefer not to shift your existing assay, since the expense of validation could be exceeding what it costs, or the savings achieved by migrating it elsewhere. That's a positive signal for us, because we're noticing that a large share of the assets customers are migrating are in fact either larger panels or deeper sequencing, and because of that the elasticity continues to play out. And at this point we anticipate our customers will do so. I mean, that aligns with what we expect to observe. As we've stated, over 40% of our placements involve clinical, and we anticipate that figure will keep rising in the period ahead. So I realize there's a worry circulating that we will definitely encounter a cliff. That isn't our reading of it. That isn't the way we discuss it with our customers. What we observe is a transition taking place, and it will roll out in stages, and as a result track the path we've witnessed across recent quarters of transition.
Ankur Dhingra
executiveSo, Tycho, up to this point in the transition — and yes, I've only been around six months and have watched two quarters — whenever customers make the switch, the elasticity plus the greater throughput moving through the instrumentation is sort of unfolding as expected. What I described on the Strategy Day, we witnessed just a slight pickup of that over the quarter. GB shift growth remained quite strong, and with the transition running higher, the price impact came in higher as well. Even so, taken together, we managed to increase consumables at a high single-digit rate during this quarter, since a bigger share of the business has by now moved into X, correct? I mean beyond 55, so more than half of volumes have already transitioned. That leaves us well positioned for a greater portion of the GB growth to begin converting into revenue.
Jacob Thaysen
executiveAlso, Tycho, regarding what you described as multi-year contracts, I believe you mean what we refer to as the open offer letter. This isn't tied to a particular instrument, so those agreements remain valid, or they will carry on with the X.
David Westenberg
analystSo I'll expand on the two questions Doug raised — I believe that came from Doug and Tycho — regarding how demand responds to price changes. I apologize for harping on this, but that cliff is a major subject that investors keep bringing up. Could you perhaps offer us some kind of framing around new assays hitting the market, or something along those lines, that would help illustrate how this entire GB is in fact becoming — how all these flow cells are in fact turning into positive net revenue? I realize you've already provided plenty of detail, but I still want to add a bit more on top of it. Then, regarding fourth quarter seasonality, adding to that portion of the question, my understanding is that only 1 year has seen Q4 come in below Q3. Could you discuss perhaps some of the budget flush dynamics that aren't occurring this quarter? I'm aware there's clearly a low throughput weight involved there. That said, low throughput represents a percentage of capital sales. I mean, it's quite small relative to the overall P&L; so thank you very much.
Jacob Thaysen
executiveYes, David. Let me get into that. There are 2 things to consider when you look at those assays. I've certainly talked with customers who chose to make larger assays. So if they have an oncology assay, they've chosen to add additional markers, and perhaps methylation markers too, on all the things that need significantly deeper sequencing; so we're seeing that occur at this moment. Beyond that, what ought to be truly encouraging is that we are, as Ankur also mentioned, still witnessing robust volume growth across both the clinical and academic customer segments. So that really demonstrates that, while the X is what's being offered and most of that volume clearly originates from the X; so despite the fact that the X carries a lower price, we find the elasticity genuinely does work across both the clinical and the research market; we aren't seeing many customers at present who merely switch over and keep the same volume. The majority are moving to the X while also generating additional volume. Ankur, would you like to?
Ankur Dhingra
executiveNot at all, that's fine. Regarding what you asked about seasonality, looking at our guidance on a sequential basis, I'd say instruments, since we're keeping things at minus mid — what was it — a 30% sequential drop, instruments would actually still be higher than Q3, and when I mentioned seasonality around a Q3-to-Q4 decline, that was really aimed at consumables, where fewer working days could mean less testing and lower inventory, that sort of thing. Another point I'd like to remind everybody of — I believe we've mentioned this previously — is that our X consumables continue to have a comparatively shorter shelf life than what 6K had. So certain inventory patterns could show up as we close out the year. Should there be fewer tests run or fewer working days available, our customers might decide to handle their inventory in line with that.
Conor McNamara
analystI want to dig a bit more into the revision to total revenue guidance — it comes to 20 million to 25 million, as I figure it, across the year, and my guess is the bulk of that sits in Q4. Can we safely say it's entirely within instruments? If that's the case, could you walk through where the pressure is showing up — is it entirely in low and mid throughput, or are there other spots where revenue is coming out of the guidance?
Ankur Dhingra
executiveYes, fair question. You've got it right — measured against the midpoint, the figure falls within the range you just mentioned. To step back a moment: as we reviewed Q3 and how quickly we closed business, we felt really good about the way consumables turned out. On the instrument side, though, looking at how fast deals are closing, how we read the funnel, how we read closures, and with our sales organization reporting back to us — that tempo has grown less steady recently. That's the core reason we went back and said that should conditions stay the same — should that same unevenness persist — pinning down how much year-end business we'll book becomes difficult. That was the central logic driving the guidance revision. As we worked through it, we pointed out that a better framing is to expect us to land nearer the bottom of our TVS guidance rather than at the middle. That's how we arrived at roughly the 10.70-ish figure; now, when modeling, I'd suggest pulling the reduction in about equal parts from instruments, consumables, and services. That's likely the cleanest approach, since our thinking centers on deal closure velocity rather than flagging softness in any one area. So you could remove a third from each of the three. I single out services as well because we hold certain CDX deals. Our TSO comp assay, as you're aware, was approved by FDA not long ago. A handful of CDS agreements are linked to it. Milestones under those CDS agreements are sliding into next year. So I'd probably spread roughly a third evenly among the three lines.
Dan Arias
analystJacob, throughout this year, you folks have quite regularly pointed to the macroeconomic situation as a drag on placements. Once the calendar turns and we're in 2025, it doesn't seem like a major shift is on the way; so what makes you comfortable that this headwind is truly easing? What signals should we watch for that could push the placement rate in a positive direction?
Jacob Thaysen
executiveYes, Dan, you're absolutely correct. I look forward to the day when macro headwinds no longer come up on these calls for any of us; and as we've said previously, I do believe that, at least from where Illumina sits, growth in consumables serves as the early sign that a turnaround is beginning. That being said, if I take a look, as we discussed on strategy day, it's currently simpler to gaze a few years ahead since our models show that as we move the business onto the X. Yet calling things quarter-by-quarter remains very hard right now, or even beyond a single quarter; nonetheless, we genuinely are observing progress, green shoots, in various areas. As you noted, consumables appear stronger; we think the MiSeq i100 is providing us with some momentum. But with the election approaching, tomorrow will change everything once more. So we'll see. And at the moment, we're handling things quarter-by-quarter.
Ankur Dhingra
executiveThen the single point I'd put on top of that is this: for our business, the consumables line serves as the proper forward-looking signal, exactly as Jacob described. And part of our argument concerning consumables getting back to expansion, and after that serving as the base for what comes next, is more or less unfolding during the latter portion of this period. On the instruments side, sure, like Jacob mentioned, we simply need to watch how it develops.
Patrick Donnelly
analystAnkur, this is likely aimed at you regarding margins. It's good to see gross margins return to above 70 during this quarter. Could you discuss the cost reduction initiatives? Clearly, you've got the $100 million for this year — how is that going; and then that additional $200 as we look ahead, just the timing of it. Clearly, we have that longer-term margin expansion target of roughly the 500 bps across the coming three years. But could you just address, I suppose, the effect next year from the cost-cutting side and then any offsets we ought to consider on margins as we think about that high-level framework for 2025, any headwinds we should know about would be useful. Thank you, guys.
Jacob Thaysen
executiveYes. So before Ankur gets into the specifics of the details here, I just want to note once more that the outcome we're seeing today reflects a very deliberate focus across the entire company, Illumina, since I arrived here, of truly making an effort, saying, look, there may still be a stretch ahead where we'll face challenges on the top line. But in the meantime, we really want to establish the culture for the proper focus on operational excellence and ensure we set the right priorities to both generate efficiencies within the company but also generate a much better approach to running the company. And that extends far beyond merely examining operations. It spans from the commercial organization all the way through R&D operations and everything we do. And I genuinely believe, as I've stated previously, this is what good companies do. And that won't shift on the day that we see substantial top-line improvements. I genuinely believe this is what a good company will look like also going forward and how we shape the culture. So, Ankur, do you want to get into the details?
Ankur Dhingra
executiveNot at all, Jacob. And that’s already happening during the past six months while we’ve stepped in, sharing that same message throughout the company, setting out our plans for where a portion of those savings might be found. At the same time, from a cultural standpoint, what we’re seeing is that teams themselves, working from the ground up, are beginning to propose initiatives and put forward concepts about where possible efficiency improvements might exist, and that is precisely the kind of culture we aim to build. So I’m very happy with the direction this is taking. Turning to what you asked, I feel confident about the $100 million in savings for this year. If you just take the guidance as a whole, even at that 10.70 operating margin, we’re discussing a 3% decline in revenue compared with the prior year alongside a fairly significant margin increase, now weighted more toward gross margin in this year; and we’ve managed to largely offset all of our inflationary pressures, or a significant share of them, across 2024. So I feel good about that $100 million this year. Regarding the $200 million ahead, or the 500 basis point margin expansion, as I mentioned on the Strategy Day, our emphasis will remain on removing costs from both COGS and operating expenses; we have a set of strategies, with some already being executed and others in early execution, related to establishing global capability centers; we’ve relocated our shipping line changes. We’re bringing together certain portions of our manufacturing lines at specific sites. We’re reviewing our R&D programs, and so on. So we’re examining this across the board. As for where we’re putting money back in, we’ll probably invest somewhat more in sales and marketing than we do at present. When it comes to headwinds ahead, I don’t see anything other than the typical inflationary pressure, correct? Each year, there will be merit and inflation that show up, and we’ll discover ways to counter that as part of reducing our expenses; but overall, returning to our strategy of expanding 500 basis points over the coming three years, I feel good about it.
Subha Nambi
analystYou brought in close to $300 million of free cash flow. Was there anything unusual during the quarter? What's the trajectory from here? And do sufficient levels exist to produce strong FCF starting at these levels? And extending from that, might you pursue a more aggressive buyback given where the stock sits now?
Jacob Thaysen
executiveYes, Subha. I appreciate that. And to begin, I am, naturally, quite happy with where we stand today regarding our cash generation, particularly after we refocused the company on its core business. And I believe you're beginning to observe that the model is starting to work; we're producing a good amount, excellent cash generation. And as we also said at our Strategy Day, we will begin to execute on our capital allocation strategy. And you'll see us doing that this quarter. We have begun to do so. Our focus would be on both, naturally, stock repurchases, but also, naturally, on M&A. And we did both during this quarter with the acquisition of Fluent, which we completed in this quarter here, but also, naturally, began to buy back shares. So, Ankur?
Ankur Dhingra
executiveAbsolutely, Jacob. And I appreciate the question, Subha. We're really pleased with how the business is generating cash. There's nothing significant or out of the ordinary when it comes to the conversion from net income to free cash flow. I expect we'll stay comfortably over that 100 mark, and actually even nearer to 150% — that's roughly where we landed this quarter, and that's the kind of range I see for us in the near term. So from an operational standpoint, cash generation is extremely strong. Looking further out, over the coming 3 to 4 years, I do think FCF conversion will come down somewhat. Part of that is because as we adopt various expense controls while managing our capex, certain items like depreciation and stock-based compensation will decline as well. Those two are among the elements that drive the elevated FCF conversion; still, I expect it to stay comfortably above 100% on the whole. So we're in a solid cash-generating position; and as you noticed, we've begun — as Jacob mentioned — putting that cash to work. That's what we intend to do. Our plan is to start channeling this cash back into the core business to drive revenue growth and also to repurchase shares. Regarding buybacks and the broader strategy, what we presented on Strategy Day was that our primary emphasis is on growing revenue. We want to repurchase shares at minimum enough to cover anti-dilution so the share count stays flat at least, and then act opportunistically beyond that. On the M&A front, we plan to stay concentrated on tuck-in style acquisitions — things that can be revenue-accretive for our businesses and bring in those technologies. And we'll keep managing our balance sheet tightly. We de-levered somewhat this quarter. At this point, we have no other bonds maturing in the near term, but we'll go on handling the balance sheet fairly conservatively going forward.
Sung Ji Nam
analystI was hoping you could go into a little more detail about what's happening in the end markets, particularly Europe versus the Americas. When you look at Europe, the growth you've posted this year has held fairly steady on both a year-over-year and a sequential basis. I'm simply curious about what's driving that, and whether those drivers differ at all from the macro picture you're seeing in the Americas. Thank you.
Jacob Thaysen
executiveThat's exactly correct. We're definitely happy with how we've done in Europe; it's encouraging to see such consistent results even while facing some difficult challenges, including conditions in Europe as well. And we expect that to carry on through the coming stretch of time. When you turn to the Americas, to the U.S., that's likewise the region where competition is putting greater pressure on mid-throughput, and it's also where we shipped considerably more of the X instrument during the prior year, which makes the comparison somewhat harder in the U.S. than in Europe. So we expect to keep looking strong in Europe as we move ahead, and the comparisons will get somewhat easier for the U.S. as we move ahead.
Ben Mee
analystHello, I'm Ben, covering for Mason. I appreciate you taking my question. I was wondering if you might walk us through what's possible in single cell, and whether you could describe your view of the Fluent position — whether it's about expanding the total addressable market being served, or perhaps capturing business from competitors in that area. If you could address those competing dynamics, that would be wonderful. Thanks very much.
Jacob Thaysen
executiveYeah, thank you for asking. We're definitely thrilled about buying Fluent, and we genuinely think we can create an exceptionally robust workflow that will benefit a large number of our clients. Since there's no need for capital layout upfront, getting started with single-cell experiments is actually quite straightforward. Plus, when you're running at very high volume, the cost for each cell experiment comes down enough to enable an enormous number of single-cell experiments. So my view is that acquiring Fluent is expanding the market opportunity for everyone involved. At the same time, even though Illumina now has its own sample prep offering for single cell, we remain strongly committed to backing our existing partners so they can thrive on our platforms. Helping our customers succeed in single cell is our core focus. I genuinely think that single cell is going to serve as an enormous cornerstone, above all, within research across the coming stretch of time. And you gain remarkable insight by means of single cell; so honestly, I hold a very optimistic view regarding the single cell opportunity. And I genuinely think that by concentrating on our customers and whatever they require and making certain we're able to serve them, regardless of whether they pick the Fluent or select one of our partners, we'll ensure that they succeed. And that's going to make every one of us successful moving ahead.
Dan Leonard
analystI'd appreciate some assistance in trying to get a clearer picture of what the MiSeq 100 launch will do. How has that low throughput sales category been trending? That would help me think through what happens if things shift. Then I have a question about the XLEAP launch on the NextSeq. What effect has that had? Has it changed how consumables are selling on that mid throughput line at all?
Jacob Thaysen
executiveSure, I'll begin with the MiSeq. With the MiSeq i100, we're quite enthusiastic about introducing a brand-new instrument offering for the low throughput portion of the market. As you're aware, over 10 years have passed since the MiSeq was introduced, and the MiSeq i100 will now be the very best option available in that segment. Our emphasis is on making it simple for users, simple to run. There's no longer any need to keep reagents in a freezer, or to ship reagents or consumables that way; that really simplifies things because you're able to take them straight out. You can unwrap, tear open the packaging and immediately use the consumables rather than preparing them first; so we anticipate customers will respond very positively. We also believe certain customers who might otherwise have chosen a mid-throughput instrument could instead opt for the MiSeq i100, given the strong advantage it delivers for them. Naturally, because our low throughput lineup was due for a refresh, we've noticed somewhat softer performance in that area. So we think that across the coming 12 to 18 months, there will be an improvement in that area. As we've mentioned previously, we don't anticipate much of an effect on Q4, but we do expect the impact to begin in 2025.
Ankur Dhingra
executiveTo give you a sense of scale here, Dan — when you look at the low throughput instruments side of things in dollar figures, it accounts for under 1%, or roughly 1%, of the revenue we bring in. So it's a technology that generates real excitement, and Box <<inaudible>> has existed for more than 10 plus years at this point. And the level of interest we're seeing is significant. We're also gaining additional call points with customers where we can discuss a whole portfolio too. But as far as shifting the total revenue figure for Illumina goes — that's just to help you get a sense of the proportions.
Jacob Thaysen
executiveRight. And regarding the active chemistry, we've noticed quite a bit of interest there. Over 60% of those using our NextSeq 1K and 2K have gotten the software, and as a result, they're beginning to adopt that chemistry too. So the reception has been really positive. We're going to remain fully dedicated to staying competitive within the mid-throughput space. And I'm genuinely enthusiastic about what lies ahead there as well.
Salli Schwartz
executiveWe appreciate you being here with us. Just a note that you can find a replay of this call in the Investor section of our website; that wraps up today's call; and we hope to connect with you at upcoming conferences and other events.
Operator
operatorOnce more, everyone, that brings us to the end of today's call, and we appreciate your joining us. At this point, you're welcome to hang up. Have a wonderful day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.